Home

helps physicians and healthcare professionals

Erectile Dysfunction

helps physicians and healthcare professionals

Doctor123.org

helps physicians and healthcare professionals

Genito-Pelvic Pain/Penetration Disorder (Vaginismus)

para />
  • May first present during evaluation for infertility

  • Pregnancy can occur in patients with genito-pelvic pain/penetration disorder when ejaculation occurs on the perineum.

  • Vaginismus may be an independent risk factor for cesarean delivery.

á

EPIDEMIOLOGY


Incidence
The incidence of vaginismus is thought to be about 1-17% per year worldwide. In North America, 12-21% of women have genito-pelvic pain of varying etiologies (2). á
Prevalence
  • True prevalence is unknown due to limited data/reporting.
  • Population-based studies report prevalence rates of 0.5-30%.
  • Affects women in all age groups.
  • Approximately 15% of women in North America report recurrent pain during intercourse.

ETIOLOGY AND PATHOPHYSIOLOGY


Most often multifactorial in both primary and secondary vaginismus á
  • Primary
    • Psychological and psychosocial issues
      • Negative messages about sex and sexual relations in upbringing may cause phobic reaction.
      • Poor body image and limited understanding of genital area
      • History of sexual trauma
    • Abnormalities of the hymen
    • History of difficult gynecologic examination
  • Secondary
    • Often situational
    • Often associated with dyspareunia secondary to:
      • Vaginal infection
      • Inflammatory dermatitis
      • Surgical or postdelivery scarring
      • Endometriosis
      • Inadequate vaginal lubrication
      • Pelvic radiation
      • Estrogen deficiency
    • Conditioned response to pain from physical issues previously listed

RISK FACTORS


  • Most often idiopathic
  • Although the exact role in the condition is unclear, many women report a history of abuse or sexual trauma.
  • Often associated with other sexual dysfunctions

COMMONLY ASSOCIATED CONDITIONS


  • Marital stress, family dysfunction
  • Anxiety
  • Vulvodynia/vestibulodynia

DIAGNOSIS


DSM-5 has combined vaginismus and dyspareunia in a condition called genito-pelvic pain/penetration disorder. á

HISTORY


  • Complete medical history
  • Full psychosocial and sexual history, including the following:
    • Onset of symptoms (primary or secondary)
    • If secondary, precipitating events, if any
    • Relationship difficulty/partner violence
    • Inability to allow vaginal entry for different purposes
      • Sexual (penis, digit, object)
      • Hygiene (tampon use)
      • Health care (pelvic examination)
    • Infertility
    • Traumatic experiences (exam, sexual, etc.)
    • Religious beliefs
    • Views on sexuality

PHYSICAL EXAM


  • Pelvic examination is necessary to exclude structural abnormalities or organic pathology.
  • Educating the patient about the examination and giving her control over the progression of the examination is essential, as genital/pelvic examination may induce varying degrees of anxiety in patients.
  • Referral to a gynecologist, family physician, or other provider specializing in the treatment of sexual disorders may be appropriate.
  • Contraction of pelvic floor musculature in anticipation of examination may be seen.
  • Lamont classification system aids in the assessment of severity
    • First degree: Perineal and levator spasm relieved with reassurance.
    • Second degree: Perineal spasm maintained throughout the pelvic exam.
    • Third degree: levator spasm and elevation of buttocks
    • Fourth degree: levator and perineal spasm and elevation with adduction and retreat

DIFFERENTIAL DIAGNOSIS


  • Vaginal infection
  • Vulvodynia/vestibulodynia
  • Vulvovaginal atrophy
  • Urogenital structural abnormalities
  • Interstitial cystitis
  • Endometriosis

DIAGNOSTIC TESTS & INTERPRETATION


No laboratory tests indicated unless signs of vaginal infection are noted on examination. When diagnosing of this disorder has been conducted, five factors should be considered. á
  • Partner factors
  • Relationship factors
  • Individual vulnerability factors
  • Cultural/religious factors
  • Medical factors

Test Interpretation
Not available; may be needed to check for secondary causes á

TREATMENT


  • Genito-pelvic pain penetration disorder may be successfully treated (2)[B].
  • Outpatient care is appropriate.
  • Treatment of physical conditions, if present, is first line (see "Secondary"Ł under "Etiology and Pathophysiology"Ł).
  • Role for pelvic floor physical therapy and myofascial release
  • Some evidence suggests that cognitive-behavioral therapy may be effective, including desensitization techniques, such as gradual exposure, aimed at decreasing avoidance behavior and fear of vaginal penetration (3)[A].
  • Based on a Cochrane review, a clinically relevant effect of systematic desensitization cannot be ruled out (4)[A].
  • Evidence suggests that Masters and Johnson sex therapy may be effective (5)[B].
    • Involves Kegel exercises to increase control over perineal muscles
    • Stepwise vaginal desensitization exercises
      • With vaginal dilators that the patient inserts and controls
      • With woman's own finger(s) to promote sexual self-awareness
      • Advancement to partner's fingers with patient's control
      • Coitus after achieving largest vaginal dilator or three fingers; important to begin with sensate-focused exercises/sensual caressing without necessarily a demand for coitus
      • Female superior at first; passive (nonthrusting); female-directed
      • Later, thrusting may be allowed.
  • Topical anesthetic or anxiolytic with desensitization exercises may be considered.
  • Patient education is an essential component of treatment (see "Patient Education"Ł section).

MEDICATION


  • Antidepressants and anticonvulsants have been used with limited success. Low-dose tricyclic antidepressant (amitriptyline 10 mg) may be initiated and titrated as tolerated (6)[B].
  • Topical anesthetics or anxiolytics may be utilized in combination with either cognitive-behavioral therapy or desensitization exercises as noted above (4)[B].
  • Botulinum neurotoxin type A injections may improve vaginismus in patients who do not respond to standard cognitive-behavioral and medical treatment for vaginismus.
    • Dosage: 20, 50, and 100 to 400 U of botulinum toxin type A injected in the levator ani muscle have been shown to improve vaginismus (4)[B].
  • Intravaginal botulinum neurotoxin type A injection (100 to 150 U) followed by bupivacaine 0.25% with epinephrine 1:400,000 intravaginal injection (20 to 30 mL) while the patient is anesthetized may facilitate progressive placement of dilators and ultimately resolution of symptoms (7)[B].

ISSUES FOR REFERRAL


For diagnosis and treatment recommendations, the following resources may be consulted: á
  • Obstetrics/gynecology
  • Pelvic floor physical therapy
  • Psychiatry
  • Sex therapy
  • Hypnotherapy

SURGERY/OTHER PROCEDURES


Contraindicated á

COMPLEMENTARY & ALTERNATIVE MEDICINE


  • Biofeedback
  • Functional electrical stimulation

ONGOING CARE


FOLLOW-UP RECOMMENDATIONS


Desensitization techniques of gentle, progressive, patient-controlled vaginal dilation á
Patient Monitoring
General preventive health care á

DIET


No special diet á

PATIENT EDUCATION


  • Education about pelvic anatomy, nature of vaginal spasms, normal adult sexual function
  • Handheld mirror can help the woman to learn visually to tighten and loosen perineal muscles.
  • Important to teach the partner that spasms are not under conscious control and are not a reflection on the relationship or a woman's feelings about her partner
  • Instruction in techniques for vaginal dilation
  • Resources
    • American College of Obstetricians & Gynecologists (ACOG), 409 12th St., SW, Washington, DC 20024-2188; 800-762-ACOG. http://www.acog.org/
    • Valins L. When a Woman's Body Says No to Sex: Understanding and Overcoming Vaginismus. New York, NY: Penguin; 1992.

PROGNOSIS


Favorable, with early recognition of the condition and initiation of treatment á

REFERENCES


11 American Psychiatric Association. Diagnostic Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.22 Landry áT, Bergeron áS. How young does vulvo-vaginal pain begin? Prevalence and characteristics of dyspareunia in adolescents. J Sex Med.  2009;6(4):927-935.33 ter Kuile áMM, Both áS, van Lankveld áJJ. Cognitive behavioral therapy for sexual dysfunctions in women. Psychiatr Clin North Am.  2010;33(3):595-610.44 Melnik áT, Hawton áK, McGuire áH. Interventions for vaginismus. Cochrane Database Syst Rev.  2012;(12):CD001760.55 Pereira áVM, Arias-Carri │n áO, Machado áS, et al. Sex therapy for female sex dysfunction. Int Arc Med.  2013;6(1):37.66 Crowley áT, Goldmeier áD, Hiller áJ. Diagnosing and managing vaginismus. BMJ.  2009;338:b2284.77 Pacik áPT. Vaginismus: review of current concepts and treatment using botox injections, bupivacaine injections, and progressive dilation with the patient under anesthesia. Aesthetic Plast Surg.  2011;35(6):1160-1164.

ADDITIONAL READING


  • Basson áR, Wierman áME, van Lankveld áJ, et al. Summary of the recommendations on sexual dysfunctions in women. J Sex Med.  2010;7(1, Pt 2):314-326.
  • Jeng áCJ, Wang áLR, Chou áCS, et al. Management and outcome of primary vaginismus. J Sex Marital Ther.  2006;32(5):379-387.
  • Pacik áPT. Understanding and treating vaginismus: a multimodal approach. Int Urogynecol J.  2014;25(12):1613-1620.
  • Reissing áED, Binik áYM, Khalif ę áS, et al. Etiological correlates of vaginismus: sexual and physical abuse, sexual knowledge, sexual self-schema, and relationship adjustment. J Sex Marital Ther.  2003;29(1):47-59.
  • Simons áJS, Carey áMP. Prevalence of sexual dysfunctions: results from a decade of research. Arch Sex Behav.  2001;30(2):177-219.
  • ter Kuile áMM, van Lankveld áJJ, de Groot áE, et al. Cognitive-behavioral therapy for women with lifelong vaginismus: process and prognostic factors. Behav Res Ther.  2007;45(2):359-373.

SEE ALSO


Dyspareunia; Sexual Dysfunction in Women á

CODES


ICD10


  • N94.2 Vaginismus
  • N94.1 Dyspareunia

ICD9


  • 625.1 Vaginismus
  • 625.0 Dyspareunia

SNOMED


  • 266598008 vaginismus due to non-psychogenic cause (finding)
  • 71315007 Dyspareunia (finding)
  • 198402002 Dyspareunia due to non-psychogenic cause in the female

CLINICAL PEARLS


  • In a patient with suspected genito-pelvic pain penetration disorder, a complete medical history, including a comprehensive psychosocial and sexual history and a patient-centric, patient-controlled educational pelvic exam should be conducted.
  • This condition can be treated effectively.
  • Cognitive-behavioral therapy may be effective for the treatment of this condition.
  • Botox injection therapy is in the experimental stages but looks promising for the treatment of vaginismus. Bupivacaine and dilation under general anesthesia has also been tried as a treatment for vaginismus.
Copyright © 2016 - 2017
Doctor123.org | Disclaimer